Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
NU-DERM CLEAR
Overview
What is NU-DERM CLEAR?
Hydroquinone is 1, 4-benzenediol. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designed as p-dihydroxybenzene; the empirical formula is CHO; molecular weight is 110.11 g/mol. The chemical structure is in the diagram below.
Each gram of Obagi Nu-Derm Clear contains:
Active ingredient:
Inactive ingredients:
Each gram of Obagi Nu-Derm Blender contains:
Active ingredient:
Inactive ingredients:
Each gram of Obagi Nu-Derm Sunfader contains:
Active ingredients:
Inactive ingredients:
What does NU-DERM CLEAR look like?
What are the available doses of NU-DERM CLEAR?
Sorry No records found.
What should I talk to my health care provider before I take NU-DERM CLEAR?
Sorry No records found
How should I use NU-DERM CLEAR?
For the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.
A thin application should be applied once or twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sunblocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring.
What interacts with NU-DERM CLEAR?
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
What are the warnings of NU-DERM CLEAR?
Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental.
Hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.
Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, product should be discontinued and physician consulted. Close patient supervision is recommended.
Warnings: Avoid contact with eyes, nose, mouth, and lips.In case of accidental contact, patient should rinse thoroughly with water and contact a physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people
What are the precautions of NU-DERM CLEAR?
(Also see )
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C
Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers
It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage
Safety and effectiveness in children below the age of 12 years have not been established.
What are the side effects of NU-DERM CLEAR?
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and the physician notified immediately.
What should I look out for while using NU-DERM CLEAR?
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
Hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.
Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, product should be discontinued and physician consulted. Close patient supervision is recommended.
Warnings: Avoid contact with eyes, nose, mouth, and lips.In case of accidental contact, patient should rinse thoroughly with water and contact a physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people
What might happen if I take too much NU-DERM CLEAR?
Sorry No Records found
How should I store and handle NU-DERM CLEAR?
Protect from light and moisture. [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP.Store the unit-dose blister packages in the carton until contents have been used.Protect from light and moisture. [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP.Store the unit-dose blister packages in the carton until contents have been used.Protect from light and moisture. [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP.Store the unit-dose blister packages in the carton until contents have been used.Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36Obagi Nu-Derm Clear is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-101-36Obagi Nu-Derm Blender is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-100-36Net wt. 1 oz. (28 g) bottleNDC 62032-100-10Obagi Nu-Derm Sunfader is available as follows:Net wt. 2 oz. (57 g) bottleNDC 62032-116-36
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents contained in Obagi Nu-Derm Sunfader and Obagi Nu-Derm Sun Shield Matte Broad Spectrum SPF 50.
Non-Clinical Toxicology
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.Hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.
Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, product should be discontinued and physician consulted. Close patient supervision is recommended.
Warnings: Avoid contact with eyes, nose, mouth, and lips.In case of accidental contact, patient should rinse thoroughly with water and contact a physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension.
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents.
(Also see )
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and the physician notified immediately.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).